Considerate perspective from Marcus Schindler of Novo Nordisk in Endpoints News as he discusses the next innovation hurdle for their programs - scalability. "When we’re starting our programs, we’re now thinking about — is it scalable, how can we ever get to tens, or hundreds, of millions of patients with the chemistry?” he said. Bit more background from the operator's perspective is covered by eloquent Rodney Lax's article, "Nice drug... if you can get it" which offers insightful commentary on the topic. Another great read is Boston Consulting Group (BCG) & Synonym's "Breaking the barrier cost on manufacturing". We at Constructive Bio are pioneering the future of biomanufacturing with our revolutionary platform, designed to harness the power of programmable molecules with exotic building blocks through an innovative approach to sense codon reassignment. Our technology stands at the forefront of biotechnology, offering unprecedented fidelity and specificity in the production of complex biomolecules. What sets our platform apart is its unparalleled flexibility and scalability. We are not just experimenting with theoretical models; we are redefining the boundaries of what's possible in bioprocessing. Our approach ensures that as demand grows, our production processes can scale seamlessly, without sacrificing quality or efficiency. With Constructive Bio, we're not just creating molecules; we're building the foundation for the next generation of exciting bioproducts made at scale. Link: https://lnkd.in/eAsDfT8h https://lnkd.in/ep3rDncb https://lnkd.in/eRD_CpHY
Ola (Aleksandra) Wlodek’s Post
More Relevant Posts
-
Get a glimpse into the future of drug development with this episode of #AViewOn Drug Bioavailability Enhancement, exploring how PBPK modeling enhances drug bioavailability and paves the way for personalized medicine. Join experts Deanna Mudie and John DiBella in this discussion on making medications safer and more effective. Find the full episode here: https://lnkd.in/d34iFzHF
-
-
By reducing the size of drug particles, #nanoforming can open up new opportunities – from increasing bioavailability to enabling sustained drug delivery. Discover the potential benefits supported by case studies. https://lnkd.in/eK5BDcBp Source: Nanoform #drugdelivery #bioavailability
Nanoforming - The Patient- And Planet-Centric Approach From Increasing Bioavailability To Enabling Sustained Drug Delivery
drugdeliveryleader.com
-
Despite fluctuating market dynamics in #biopharma, one thing remains clear: adaptation is key. Kura CEO Troy Wilson, PH.D., J.D. joined fellow panelists at Fierce JPM Week to discuss the #IRA and its impact on drug discovery and development. Here, he emphasizes the need for balance between societal incentives and scientific progress to efficiently drive drug development forward in the interest of helping patients. Hear more in the clip below and read more of his insights here: https://lnkd.in/g8FgCRCD
-
A Comprehensive and Flexible Approach to CMC for Fab and Fc-Fusion Development Programs Read this whitepaper to: - Gain insights into the diverse and complex structures of new molecular formats, often encompassing multiple chains and multiple domains - Understand the unique challenges faced during the process development and manufacture of these advanced proteins - Explore how characterising these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat Download Whitepaper https://lnkd.in/ewzPB6UE Brought to you by Lonza #DrugDevelopment #DrugDiscovery #LifeSciences
-
-
Unlock new possibilities in drug discovery with this application note on targeted protein degradation. Explore how our no-wash HTRF platform simplifies the process, providing more accurate and reliable results. Dive into the details and revolutionize your research today. http://ms.spr.ly/6048lYf9G #DrugDiscovery
-
-
"Strategically Innovative Biopharmaceutical Formulation Scientist | Protein Therapeutics | Lyophilization | GMP Expertise"
🌟 Exciting Update Alert! 🌟 🔬 Get ready to explore the cutting-edge world of biotherapeutics and biosimilars with our latest review article titled "WHO Standards for Biotherapeutics: Evaluating Complex Biological Products," authored by the esteemed experts Ivana Knezevic and Elwyn Griffiths. 📚 This illuminating article delves into the intricate regulatory processes governing biotherapeutic products, offering insights into the evolving landscape of biosimilars evaluation. From the essential role of the World Health Organization to the scientific challenges posed by biosimilars, this article promises to be a thought-provoking read for professionals and enthusiasts alike. 🌍 Let's come together to celebrate the collaboration and expertise behind this groundbreaking article, and stay tuned for its release as we prepare to unravel the complexities of biotherapeutics regulation! #Biotherapeutics #Biosimilars #RegulatoryStandards #WHO #Science #Innovation #StayTuned 🚀
-
#Researchers: Therapeutic peptides are typically administrated subcutaneously as their oral bioavailability is poor. To positively impact climate and sustainability, there is a high need to replace today’s single-use drug delivery devices with better solutions. How would you propose to develop a drug delivery device with a more favorable ecological footprint, that may reach market maturity within five to ten years from now? Your proposal should address the technological, conceptual, and economic hurdles associated with the development of a next generation drug delivery device. Learn more on #opnMe https://lnkd.in/egewtjfG #openscience #boehringer
-
-
Learn how scientists are using varying techniques and technologies to further their multiple sclerosis drug discovery research with this literature review. http://ms.spr.ly/6041YuP8t #lifesciences #drugdiscovery
-
-
Have you heard about Deggie? Our integrated laboratory automation machine is a tool that enables our #TPD science, allowing us to efficiently manage the wide array of biochemical and cellular assays needed to screen and characterize potential drug molecules. To us, Deggie symbolizes our science and the work we’ve done to create new, transformative medicines. Read Deggie’s story here: https://bit.ly/4apfeFR
-
